Related Experiment Video
Updated: May 9, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Dramatic response to Cisplatin window therapy in a boy with advanced metastatic ewing sarcoma
Antonino Trizzino1, Ottavio Ziino, Antonina Parafioriti
1Department of Pediatric Hematology and Oncology, ARNAS Civico, Di Cristina and Benfratelli Hospital, Palermo, Italy.
Journal of Pediatric Hematology/Oncology
|July 30, 2013
Summary
Ewing sarcoma (ES) is a rare bone cancer. A child with multifocal ES showed a dramatic response to cisplatin, a chemotherapy drug not typically used for ES, suggesting its potential efficacy.
Area of Science:
- Pediatric Oncology
- Medical Malignancies
- Cancer Therapeutics
Background:
- Ewing sarcoma (ES) is the second most common primary bone cancer in children and adolescents.
- ES has a high metastatic potential, leading to poor prognoses for patients with disseminated disease (<20% event-free survival).
- Current treatments involve combined chemotherapy, surgery, and radiotherapy, but cisplatin is not standard for ES.
Observation:
- A pediatric patient with multifocal ES was treated within a phase II trial.
- The trial included a single-drug 'window' therapy phase.
- The patient received two courses of cisplatin as part of this window therapy.
Findings:
- The multifocal Ewing sarcoma demonstrated a dramatic response to cisplatin treatment.
- This response was observed after only two courses of the single-drug therapy.
- The patient experienced a favorable outcome following this initial treatment.
Implications:
- Cisplatin shows potential as an effective single-agent therapy for Ewing sarcoma.
- This finding may lead to new treatment strategies for multifocal or disseminated ES.
- Further investigation into cisplatin's role in ES treatment is warranted.
